title: Acute Ischemia due to Superficial Femoral Artery Thrombosis: Results of In Situ Fibrinolysis.
abstract: BACKGROUND
  The management of acute ischemia due to the thrombosis superficial femoral artery (SFA) stents is complex. In situ arterial fibrinolysis, still not evaluated in this indication, would allow, by lifting the ischemia and uncovering its cause, to avoid thrombectomy, endovascular recanalization, or arterial bypass. The purpose of the study was to evaluate the effectiveness, the complications, and the assisted secondary patency of in situ fibrinolysis for thrombosis of SFA stents.
  
  
  METHODS
  We conducted a retrospective monocentric study with prospective collection of the data. Between October 2011 and December 2014, 86 in situ fibrinolysis procedures were carried out for acute lower limb ischemia. Twelve procedures were carried out for acute ischemia due to the thrombosis of SFA stents. Clinical success was defined by the lifting of acute ischemia. The causes of thromboses, the complications related to the fibrinolysis, and the secondary assisted patency were analyzed.
  
  
  RESULTS
  The mean age of the patients was 66.3 (55-90) years. The average length of the stents was 119.3 (18-270) mm. In 10 patients, the thrombosis extended in the full length of the artery. The average time between the implantation of the stent and the initiation of the fibrinolysis was 180 (11-369) days. The average time between the beginning of the symptoms and fibrinolysis was 5 (0-12) days. The average duration of treatment was 46 (24-72) hr. Clinical success was obtained in all the patients. Diagnosed isolated or associated lesions were a progression of the atheromatous disease upstream or downstream of the stent in 6 cases, and an isolated intrastent restenosis in 3 cases. In 2 cases, no obvious cause was found. One or more additional endovascular procedures were carried out in 9 cases at the end of the fibrinolysis, and consisted of a transluminal intrastent angioplasty with an active balloon in 5 cases, an additional stenting in 3 cases, and the stenting of upstream or downstream arteries in 5 cases. Secondary assisted patency was 100% at 5 months. No major hemorrhagic complication was observed. Two false aneurysms at the site of femoral puncture were observed.
  
  
  CONCLUSIONS
  Our results suggest that ischemia due to the thrombosis of SFA stents can be dealt with first intention in situ fibrinolysis which allows the endovascular treatment of the causal lesion, thus avoiding thrombectomy or bypass.
authors.affiliation: Service de chirurgie vasculaire, Etablissement Edouard Herriot, Hospices Civils de Lyon, Lyon, France. Electronic address: matthieu.arsicot@gmail.com.
authors.forename: Matthieu
authors.initials: M
authors.lastname: Arsicot
authors.affiliation: Service de chirurgie vasculaire, Etablissement Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
authors.forename: Nellie
authors.initials: N
authors.lastname: Della Schiava
authors.affiliation: Service de chirurgie vasculaire, Etablissement Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
authors.forename: Tarek
authors.initials: T
authors.lastname: Boudjelit
authors.affiliation: Service de Radiologie, Etablissement Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Rouvière
authors.affiliation: Service de chirurgie vasculaire, Etablissement Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
authors.forename: Patrick
authors.initials: P
authors.lastname: Feugier
authors.affiliation: Service de chirurgie vasculaire, Etablissement Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
authors.forename: Patrick
authors.initials: P
authors.lastname: Lermusiaux
authors.affiliation: Service de chirurgie vasculaire, Etablissement Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
authors.forename: Antoine
authors.initials: A
authors.lastname: Millon
mesh_terms: D000208:Acute Disease; D001157:Arterial Occlusive Diseases / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000628:therapy*; D057510:Endovascular Procedures / Q000009:adverse effects* / Q000295:instrumentation; D005263:Femoral Artery / Q000000981:diagnostic imaging / Q000503:physiopathology; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D005602:France; D006801:Humans; D007511:Ischemia / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D012189:Retrospective Studies; D012307:Risk Factors; D015607:Stents; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000379:methods*; D013927:Thrombosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D013997:Time Factors; D016896:Treatment Outcome; D014654:Vascular Patency
chemical_list: D005343:Fibrinolytic Agents